The Research Behind What We Do
Every Vedcura protocol is traceable to published, peer-reviewed science. We do not build treatments from anecdotes. We read the literature, and we apply it with precision.
Published Scientific Papers
Years of Continuous Research
Clinical Trials Reviewed (JAMA)
Participants Across Trials
6 Landmark Studies
Discovery of Anandamide (1992)
Devane et al. — Science
First isolation of an endogenous cannabinoid produced by the human body, proving the ECS is a native biological system -- not dependent on external cannabis exposure.
View on PubMedClinical Endocannabinoid Deficiency (2004)
Russo, E.B. — Neuroendocrinology Letters
Proposed that insufficient endocannabinoid tone underlies migraine, fibromyalgia, and IBS -- explaining why these conditions overlap, resist treatment, and share similar biomarkers.
View on PubMedThe Skin's Own ECS (2009)
Biro et al. — Trends in Pharmacological Sciences
Established that the skin has a complete, functional endocannabinoid system regulating sebum, inflammation, cell turnover, and wound healing -- opening new paths for treating acne, psoriasis, and eczema.
View on PubMedCannabinoids and Chronic Pain (2012)
Xiong et al. — Nature Chemical Biology
Identified specific molecular mechanisms by which cannabinoids suppress chronic pain through glycine receptors -- a pathway entirely distinct from opioids.
View on PubMedJAMA Systematic Review (2015)
Whiting et al. — JAMA
Comprehensive review of 79 randomized controlled trials. Found moderate-quality evidence supporting cannabinoid therapy for chronic pain and spasticity, with emerging evidence for anxiety and sleep.
View on PubMedCBD and Anxiety Disorders (2015)
Blessing et al. — Neurotherapeutics
Systematic review finding substantial evidence for CBD's anxiolytic properties across generalized anxiety, social anxiety, panic disorder, OCD, and PTSD.
View on PubMedResearch by Condition
Pain and Inflammation
- Multiple RCTs show significant pain reduction with cannabinoid therapy
- Effect sizes comparable to conventional analgesics with a different side-effect profile
- Strongest evidence for neuropathic pain and cancer-related pain
- National Academies of Sciences (2017) concluded "substantial evidence" for chronic pain
Anxiety, Mood, and Sleep
- CBD demonstrates anxiolytic effects across multiple anxiety disorder subtypes
- ECS modulation supports sleep onset and quality, particularly with comorbid pain
- Endocannabinoid signaling plays a central role in stress response and fear extinction
Skin Conditions
- Cutaneous ECS regulates sebum production (acne), keratinocyte proliferation (psoriasis), and inflammation (eczema)
- CB2 activation shown to reduce inflammatory cytokine release in skin models
- Early clinical evidence supports both topical and systemic cannabinoid approaches
Hormonal and Metabolic Health
- ECS modulates cortisol via the HPA axis, thyroid function, and reproductive hormones
- Documented involvement in insulin sensitivity and metabolic regulation
- ECS dysfunction observed in PCOS, metabolic syndrome, and adrenal fatigue patterns
Vedcura's Evidence-Based Approach
We do not overpromise. If the evidence supports it, we offer it. If the evidence is emerging, we say so. If it is absent, we do not pretend otherwise.
Continuous literature review
Across cannabinoid science, neuroscience, dermatology, endocrinology, and pain medicine.
Evidence grading
Classifying the strength of evidence for each condition we treat, from robust RCT data to emerging mechanistic studies.
Protocol development
Calibrated to Indian patient populations and AYUSH regulatory requirements.
Transparency
We tell patients where the evidence is strong and where it is still growing.
The Research Is Clear
The question is whether it applies to your specific situation. Our doctors can assess your condition, explain the relevant evidence, and recommend a path forward.
Medical Disclaimer: Content on this page is for informational purposes and does not constitute medical advice. Vedcura's treatments are provided under the supervision of registered medical practitioners in compliance with AYUSH and Drugs and Cosmetics Act regulations.